Abstract: TH-PO0015
Advancing Clinical Readiness for C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Outcomes from a CME-Based Educational Intervention
Session Information
- Educational Research Within and Across Disciplines
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Educational Research
- 1000 Educational Research
Authors
- Drexel, Carole, Medlive, Needham Heights, Massachusetts, United States
- Wilson, Eve J., Medlive, Needham Heights, Massachusetts, United States
- Java, Anuja, Washington University in St Louis, St. Louis, Missouri, United States
Background
The standard of care for rare kidney diseases such as complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) is evolving rapidly, driven by the recent FDA approval of iptacopan for C3G and promising late-phase study data for pegcetacoplan. We assessed the impact of a continuing medical education (CME) initiative on clinicians’ (HCPs) competence in diagnosing C3G and IC-MPGN, and on their understanding of the emerging role of complement inhibitors (CIs) in treatment.
Methods
Two 60-minute, case-based expert panel discussions focused on the diagnosis and management of C3G and IC-MPGN were launched via live-online sessions in March 2025; they remain available on demand for one year. To extend reach, short video segments were disseminated through social media to NPI-verified nephrologists. Pre- and post-activity assessments evaluated changes in clinical knowledge and competence related to pathophysiology, diagnosis, clinical trial data, and anticipated practice changes. Paired responses were compared using chi-square tests (p < 0.05).
Results
As of May 2025, 215 HCPs participated (live: 100; enduring: 115). Adult and pediatric nephrologists comprised 52% of learners (primary care 14%; others 34%) and reported an average of five C3G-related patient visits per month. Participation in the CME activity significantly improved knowledge and competence across key domains: role of the alternative complement pathway (pre: 62% vs. post: 100%), role of nephritic factors (pre: 22% vs. post: 88%), appropriate diagnostic testing (pre: 58% vs. post: 80%), clinical data with CIs (pre: 38% vs. post: 92%). Additionally, 27% of participants reported an intention to change their pharmaceutical or management approach for patients with C3G or IC-MPGN.
Conclusion
The findings support the value of CME in enhancing HCPs’ understanding of novel diagnostic and therapeutic strategies for rare kidney diseases. Nonetheless, low baseline performance findings underscore the need for ongoing education to address knowledge gaps and promote equitable access to emerging therapies. As the availability and experience with newer CIs increase, future studies will further inform us about changes in treatment patterns and strategies. [The CME education was supported by an unrestricted educational grant from Apellis Pharmaceuticals]